Investigational drug proven to prolong survival of ALS patients - study
The median overall survival for all CENTAUR study participants being administered AMX0035 was 6.5 months longer than the group originally randomized to placebo.
Prof. Boaz Lerner of Ben-Gurion University uses a new platform for predicting ALS disease progression(photo credit: DANI MACHLIS)ByTOBIAS SIEGAL
